세계의 신약물전달 시스템(NDDS) 시장(2023-2030년)

Global New Drug Delivery Systems (NDDS) Market Size, Share & Trends Analysis Report by Route of Administration (Oral Drug Delivery Systems (DDS), Injectable Drug Delivery Systems (DDS), Pulmonary Drug Delivery Systems (DDS), Transdermal Drug Delivery Systems (DDS), and Others ), and by Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, and Others) Forecast Period (2024-2031)

The global NDDS market is anticipated to grow at a CAGR of 21.6% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for targeted therapies. Based the increased risks associated with diabetes, there is rising demand for more specific and focused medicines for managing cardiovascular problems. NDDS provides a possibilities by allowing drugs to be delivered directly to afflicted locations, decreasing systemic side effects while increasing the effectiveness of therapy. According to the National Institute of Medicine, in October 2021, the study included 3,908 adults aged 40 to 74 years from a wide range of regions. Their cardiometabolic profiles were evaluated, and its carotid arteries were examined bilaterally. The prevalence rates of carotid plaque and diabetic mellitus (DM) were 34.4% and 10.7%, respectively. when modifying for other conventional risk factors, DM patients had higher prevalence rates of carotid plaque, total plaque number, maximum diameter stenosis (30%), and plaque (multivariable-adjusted OR 1.60 for carotid plaque, 2.06 for total plaque number, 1.3 for maximum diameter stenosis, and 2.03 for plaque score) than non-DM controls.

Segmental Outlook

The global NDDS market is segmented on the route of administration, and mode of NDDS. Based on the route of administration, the market is sub-segmented oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others. Furthermore, on the basis of mode of NDDS, the market is sub-segmented into targeted drug delivery systems, controlled drug delivery systems, modulated drug delivery systems, and others. The Injectable drug delivery systems subcategory is expected to capture a significant portion of the market share within the route of administration segment. The growth can be attributed to the growing number of vaccination's drives across the globe propelling the demand for instruments.

The Oral Drug Delivery Systems Sub-Segment is Anticipated to Hold a Considerable Share of the global NDDS Market

Among the route of administration, the digital oral drug delivery systems sub-segment is expected to hold a considerable share of the global NDDS market. The segmental growth is attributed to the demand for effective oral therapies. The desire for more effective oral medicines in a variety of disease categories, including cancer, cardiovascular, infectious, and diabetes, is a major driving force. EUDRATEC SoluFlow's ability to enable the development of enhanced oral pharmaceuticals aligns with a market demand. For instance, in March 2022, Evonik launched new EUDRATEC technology to improve solubility of oral small molecules. The EUDRATEC SoluFlow, an emulsion-based process technique, overcomes solubility constraints, allowing the development of innovative oral therapies for a variety of diseases such as cancer, cardiovascular, infectious, and diabetes.

Regional Outlook

The global NDDS market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the healthcare industry benefits from a growing population and government support.

The North America Region is Expected to Grow at a Significant CAGR in the global New Drug Delivery Systems (NDDS) Market

Among all regions, North America region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the increasing demand for effective treatments across the region. The rising incidence of long-term respiratory diseases has resulted in a high demand for more effective therapies. Customized drug delivery systems have the potential to significantly improve treatment outcomes and reduce disease severity, thus satisfying the need. According to MDPI, in August 2023, the chronic inflammatory respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD), have a significant global impact, affecting millions of people and contributing to the rise in lung disease morbidity and mortality. With over 300 million individuals globally affected by asthma and COPD becoming the third leading cause of death in 2020, there is a pressing need for more effective treatments. In recent years, targeted drug delivery systems, such as nanoparticle-based approaches, inhaled corticosteroids, novel biologicals, gene therapy, and personalized medicine, have shown promise in improving drug efficacy and reducing side effects. By utilizing nanoparticles to encapsulate and deliver drugs directly to specific cells in the lungs, researchers aim to enhance drug delivery efficiency while minimizing off-target effects, offering potential for sustained release and prolonged therapeutic effects.

Market Players Outlook

The major companies serving NDDS market includes Bayer AG, Boston Scientific Corp., Johnson & Johnson Services, Inc., and Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2022, EVERSANA, and Accord BioPharma, partnered to launched CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

The Report Covers:

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global NDDS market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abbott Laboratories
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Amgen Inc. and Amgen USA Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. AstraZeneca
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global New Drug Delivery Systems (NDDS) Market by Route of Administration
  • 4.1.1. Oral Drug Delivery Systems (DDS)
  • 4.1.2. Injectable Drug Delivery Systems (DDS)
  • 4.1.3. Pulmonary Drug Delivery Systems (DDS)
  • 4.1.4. Transdermal Drug Delivery Systems (DDS)
  • 4.1.5. Others (Nasal Drug Delivery Systems (DDS), and Implantable Drug Delivery Systems (DDS))
• 4.2. Global New Drug Delivery Systems (NDDS) Market by Mode of NDDS
  • 4.2.1. Targeted Drug Delivery Systems
  • 4.2.2. Controlled Drug Delivery Systems
  • 4.2.3. Modulated Drug Delivery Systems
  • 4.2.4. Others (Biologics-Based Drug Delivery Systems, and NanoRoute of Administration -Based Drug Delivery Systems)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. Bayer AG
• 6.2. Boston Scientific Corp.
• 6.3. Bristol Myers Squibb (BMS)
• 6.4. Celgene Corp.
• 6.5. At F. Hoffmann-La Roche Ltd.
• 6.6. GlaxoSmithKline PLC
• 6.7. Johnson & Johnson Services, Inc.
• 6.8. Merck KGaA,
• 6.9. Novartis International AG
• 6.10. Pfizer Inc.
• 6.11. Assertio Holdings, Inc.
• 6.12. Gilead Sciences, Inc
• 6.13. Medtronic Pvt. Ltd.
• 6.14. Becton, Dickinson, and Co.
• 6.15. Teva Pharmaceutical Industries Ltd.
• 6.16. Mylan N.V.
• 6.17. Cipla Ltd.